For the report, AKI was defined as the occurrence of at least 1 diagnostic code 584 (acute renal failure) or the occurrence of at least 1 procedure code of 39.95 (hemodialysis) or 54.98 (peritoneal dialysis).
The results showed no difference in the number of hospital-free days between either group but the balanced crystalloids group had a lower incidence of major adverse kidney events ≤30 days vs the saline group.
The renal analyses showed that compared to placebo, canagliflozin reduced the risk of kidney disease progression, including significantly reducing urinary albumin excretion and stabilizing estimated glomerular filtration rate (eGFR) over a study duration of more than six years.
Since oxidative stress is known to worsen DKD, study authors sought to review available data on the possible benefits of chronic antioxidant supplementation on DKD progression.
Patients with C3G experience progressive deterioration in renal function, ultimately leading to renal failure requiring dialysis and kidney transplant, if left untreated.